Literature DB >> 8600162

Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha.

S E Haynesworth1, M A Baber, A I Caplan.   

Abstract

We previously reported the purification, culture-expansion, and osteogenic differentiation potential of mesenchymal progenitor cells (MPCs) derived from human bone marrow. As a first step to establishing the phenotypic characteristics of MPCs, we reported on the identification of unique cell surface proteins which were detected with monoclonal antibodies. In this study, the phenotypic characterization of human marrow-derived MPCs is further established through the identification of a cytokine expression profile under standardized growth medium conditions and in the presence of regulators of the osteogenic and stromal cell lineages, dexamethasone and interleukin-1 alpha (IL-1 alpha), respectively. Constitutively expressed cytokines in this growth phase include G-CSF, SCF, LIF, M-CSF, IL-6, and IL-11, while GM-CSF, IL-3, TGF-beta 2 and OSM were not detected in the growth medium. Exposure of cells in growth medium to dexamethasone resulted in a decrease in the expression of LIF, IL-6, and IL-11. These cytokines have been reported to exert influence on the differentiation of cells derived from the bone marrow stroma through target cell receptors that utilize gp130-associated signal transduction pathways. Dexamethasone had no effect on the other cytokines expressed under growth medium conditions and was not observed to increase the expression of any of the cytokines measured in this study. In contrast, IL-1 alpha increased the expression of G-CSF, M-CSF, LIF, IL-6 and IL-11 and induced the expression of GM-CSF. IL-1 alpha had no effect on SCF expression and was not observed to decrease the production of any of the cytokines assayed. These data indicate that MPCs exhibit a distinct cytokine expression profile. We interpret this cytokine profile to suggest that MPCs serve specific supportive functions in the microenvironment of bone marrow. MPCs provide inductive and regulatory information which are consistent with the ability to support hematopoiesis, and also supply autocrine, paracrine, and juxtacrine factors that influence the cells of the marrow microenvironment itself. In addition, the cytokine profiles expressed by MPCs, in response to dexamethasone and IL-1 alpha, identify specific cytokines whose levels of expression change as MPCs differentiate or modulate their phenotype during osteogenic or stromagenic lineage entrance/progression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8600162     DOI: 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.0.CO;2-6

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  170 in total

Review 1.  Cardiac cell therapy: boosting mesenchymal stem cells effects.

Authors:  E Samper; A Diez-Juan; J A Montero; P Sepúlveda
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 2.  Mesenchymal stem cells: potential for therapy and treatment of chronic non-healing skin wounds.

Authors:  Giovanni Marfia; Stefania Elena Navone; Clara Di Vito; Nicola Ughi; Silvia Tabano; Monica Miozzo; Carlo Tremolada; Gianni Bolla; Chiara Crotti; Francesca Ingegnoli; Paolo Rampini; Laura Riboni; Roberta Gualtierotti; Rolando Campanella
Journal:  Organogenesis       Date:  2015       Impact factor: 2.500

3.  Mesenchymal stem cells as a gene delivery vehicle for successful islet transplantation.

Authors:  Hao Wu; Wenli Lu; Ram I Mahato
Journal:  Pharm Res       Date:  2011-04-16       Impact factor: 4.200

4.  Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses.

Authors:  Suzanne L Tomchuck; Kevin J Zwezdaryk; Seth B Coffelt; Ruth S Waterman; Elizabeth S Danka; Aline B Scandurro
Journal:  Stem Cells       Date:  2007-10-04       Impact factor: 6.277

Review 5.  New era of cell-based orthopedic therapies.

Authors:  Arnold I Caplan
Journal:  Tissue Eng Part B Rev       Date:  2009-06       Impact factor: 6.389

Review 6.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Jay K Kolls; Luis A Ortiz; Angela Panoskaltsis-Mortari; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2008-07-15

7.  A promising strategy for the treatment of ischemic heart disease: Mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats.

Authors:  Feng Gao; Tao He; HongBing Wang; ShiQiang Yu; DingHua Yi; WeiYong Liu; ZhenJie Cai
Journal:  Can J Cardiol       Date:  2007-09       Impact factor: 5.223

8.  Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells.

Authors:  Tom K Kuo; Shun-Pei Hung; Chiao-Hui Chuang; Chien-Tsun Chen; Yu-Ru V Shih; Szu-Ching Y Fang; Vincent W Yang; Oscar K Lee
Journal:  Gastroenterology       Date:  2008-03-12       Impact factor: 22.682

Review 9.  Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions.

Authors:  Jeffery J Auletta; Kenneth R Cooke; Luis A Solchaga; Robert J Deans; Wouter van't Hof
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-16       Impact factor: 5.742

10.  Biomaterials functionalized with MSC secreted extracellular vesicles and soluble factors for tissue regeneration.

Authors:  Meadhbh Á Brennan; Pierre Layrolle; David J Mooney
Journal:  Adv Funct Mater       Date:  2020-03-11       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.